Research-only notice

Prepared by: Research Desk. Sources are linked for verification.
KlowSignal summarises published research and public regulatory records about peptides studied in laboratories. All content is provided for research and educational purposes only. It is not intended for human use and it is not medical advice.
What this site does not provide
- Medical advice, diagnosis or guidance on the use of any substance in people or animals.
- Instructions on preparation, administration, amounts or schedules.
- Claims that any research compound is safe or effective in people.
Research-use-only materials
Materials labelled "research use only" are intended for laboratory research. They are not approved medicines. A supplier's certificate of analysis describes a batch; it says nothing about suitability for any use. Where a compound also exists as a regulator-approved product, that approval covers the specific product and its labelled use only.
Evidence and its limits
Many findings summarised here come from cell or animal studies, which often do not carry over to people. Each page links its primary sources so that readers can check the original records.
Health questions
This site does not answer individual health questions.
Paid links
Some pages carry paid links to a research supplier. See the affiliate disclosure.
Contact
Corrections and questions: info@zvezdaff.com.
Last updated: 21 October 2026.
More from KlowSignal
How to read a research or regulatory signal
What a cell study, a phase 3 trial, a press release or an FDA list entry can and cannot tell you, with key regulatory vocabulary and a checklist for each signal.
FDA compounding committee, July 2026: seven research peptides on the agenda
FDA's Pharmacy Compounding Advisory Committee agenda for 23–24 July 2026 lists BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. Here is what the record says.
Elamipretide (SS-31): the 2025 accelerated approval on the record
SS-31 is a Szeto-Schiller tetrapeptide studied for its binding to cardiolipin. In September 2025 FDA granted accelerated approval to elamipretide for Barth syndrome. Here is what the record shows.


